Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that it expects to be added to the small-cap Russell 2000® and all-cap Russell 3000® Indexes at the conclusion of the 2024 Russell Indexes annual reconstitution, effective after U.S. market close on June 28, 2024, according to a preliminary list of additions posted on May 24, 2024.